Abstract
Objective To evaluate the effect of remifentanil on Toll-like receptor 2 (TLR2) mRNA expression during renal ischemia-reperfusion (I/R) in rats. Methods Fifty-four male Sprague-Dawley rats, weighing 200-250 g, were randomly divided into 3 groups (n= 18 each) using a random number table: sham operation group (group S), I/R group and remifentanil group (group R). Renal I/R injury was produced by clamping the bilateral renal arteries for 45 min followed by reperfusion in I/R and R groups.Bilateral renal arteries were only exposed but not clamped in group S. Remifentanil 1.0 μg·kg-1·min-1 was infused via the tail vein starting from 15 min before ischemia until 30 min of reperfusion in group R, while the equal volume of normal saline was given instead in S and I/R groups.The animals were sacrificed at 15 min before ischemia and 6 and 24 h of reperfusion, and the renal specimens were obtained for examination of the pathological changes (with light microscope) and for determination of the contents of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) (by ELISA) and expression of TLR2 mRNA (by RT-PCR) and cell apoptosis (by double staining and flow cytometry). The apoptotic rate was calculated. Results Compared with group S, TLR2 mRNA expression was significantly up-regulated, and the contents of TNF-α and IL-6 and apoptotic rate were increased at 6 and 24 h of reperfusion in I/R and R groups.Compared with group I/R, TLR2 mRNA expression was significantly down-regulated, and the contents of TNF-α and IL-6 and apoptotic rate were decreased at 6 and 24 h of reperfusion in group R. The pathological changes were significantly attenuated in group R as compared with group I/R. Conclusion The mechanism by which remifentanil reduces renal I/R injury is related to down-regulation of TLR2 expression and decrease in TLR2 activity and inhibition of inflammatory responses in renal tissues and cell apoptosis in rats. Key words: Piperidines; Reperfusion injury; Kidney; Toll-like receptor-2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
